Daewoong Pharmaceutical Launches 'Hope Steps Campaign' to Support Children with Rare Diseases

[Asia Economy Reporter Lee Gwan-joo] Daewoong Pharmaceutical announced on the 3rd that it has launched the 'Hope Steps Campaign' to support children with rare diseases.

The campaign, prepared to coincide with Rare Disease Day on the 23rd of last month, saw voluntary participation from a total of 270 employees across Daewoong Group's headquarters, research centers, and production lines nationwide. The campaign will run throughout this month.

The Hope Steps Campaign measures the total number of steps taken by participants, and upon reaching the common goal of 10 million steps, support will be provided to children with rare diseases. The donation amount is calculated as 1 KRW per step, and upon achieving the 10 million step goal, Daewoong Pharmaceutical will provide an additional 10 million KRW as a matching grant, delivering a total of 20 million KRW to rare disease patients selected through the nonprofit organization Good People International.

Good People plans to select beneficiaries among patients under 19 years old suffering from rare diseases, considering factors such as income, medical condition, psychological and social support, and effectiveness of assistance, and then distribute the donations from Daewoong Pharmaceutical employees accordingly.

A Daewoong Pharmaceutical official stated, “We are conducting various activities to support patients suffering from rare diseases,” adding, “In addition to developing new drugs to overcome intractable diseases, we will practice ESG (Environmental, Social, and Governance) management through various social contribution activities, including the Hope Steps Campaign, to fulfill our social responsibilities.”

Daewoong Pharmaceutical is committed to overcoming rare and intractable diseases, including the development of 'DWN12088,' a fibrosis treatment drug, which is one of the representative rare diseases. DWN12088 was designated as an orphan drug by the U.S. Food and Drug Administration (FDA) in 2019 for idiopathic pulmonary fibrosis and last year for systemic sclerosis. It confirmed tolerability and safety in a Phase 1 clinical trial conducted in Australia, and this year completed Phase 2 clinical trial applications in Korea and the United States.

This content was produced with the assistance of AI translation services.